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RI~SUM#: Les auteurs ont r6alis6 quatre 6tudes prospectives dans le but d'6tudier les diff6rents facteurs 
responsables de la lib6ration d'histamine dans la p6riode p6dop6ratoire. Les r6actions allergiques vraies et 
les r6actions pseudo-allergiques ne sont pas seules en cause. De nombreux autres m6canismes d'histami- 
nolib6ration sont sugg6r6s : m6canismes neuroendocriniens, lib6ration cons6cutive ,~ des stimuli nocicep- 
tifs, facteurs cytotoxiques cons6cutifs au traumatisme tissulaire de l'acte chirurgical et lib6ration induite 
par les cytokines. Ces mdcanismes ont 6t6 mis en 6vidence darts deux 6tudes prospectives 6tudiant, l'une 
des patients lors d'une gastroscopie r6alis6e sans pr6m6dication et l'autre, des patients b6n6ficiant d'une 
chol6cystectomie p rccelioscopique. Darts une autre 6tude, une histaminolib6ration par mdcanisme pseudo- 
allergique a 6t6 not6e imm6diatement apr~s l'induction anesth6sique chez un hombre important de 
patients op6r6s pour divers acres de chirurgie g6n6rale. Dans ces deux cas, I'histaminolib6ration est 
ind6sirable car elle est ~a l'origine de sympt6mes de gravit6 variable. Les signes cliniques sont surtout 
cardiovasculaires t respiratoires alors que les signes cutan6s sont souvent absents. Les auteurs consid~- 
rent que dans la pdriode p6riop6ratoire la lib6ration d'histamine st ind6sirable dans certains cas mais 
darts d'autres elle n'a pas de cons6quences n6fastes, pouvant m6me 6tre b6n6fique. Une r66valuation des 
signes cliniques d'histaminolib6ration estn6cessaire puisque les 6tudes ont montr6 que des concentrations 
plasmatiques de 12 ng. ml -~ d'histamine souvent ne s'accompagnaient d'aucun signe cutan6. Ainsi une 
histaminolib6ration non sp6cifique n'est, le plus souvent, pas reconnue comme cause d'une hypotension 
art6rielle p6riop6ratoire n raison du manque de sp6cificit6 de ce sympt6me. Des 6tudes ult6rieures 
doivent pr6ciser le r61e des m6dicaments antihistaminiques (anti-H1 et anti-H2, doses, choix des patients, 
moment de Fadministration) darts la pr6vention de l'histaminolib6ration p6riop6ratoire. 
CLASSIFICATION OF PERIOPERATIVE HISTAMINE 
RELEASE 
In  the  last conference  on  prevent ion  of  per i -  
anaesthet ic  anaphy lac to id  react ions ,  Nancy ,  
1984 [52], a who le  ser ies of  mechan isms for  non-  
specif ic h i s tamine  re lease  was not  ment ioned at 
all [62]. Surg ica l  t rauma was inc luded,  but  on ly  
one  re ference  cou ld  be  g iven  at this  t ime [93] and  
did not  cha l lenge  the  genera l  op in ion  over  
50 years  that  ,~ h is tamine  does  not  p lay an impor -  
tant  role in ma jor  in ju ry  or  t raumat ic  shock ,  [1, 
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In  this conference  [54], however ,  a cons iderab le  
increase  of  knowledge has  to b~ repor ted  wh ich  
c reates  new hypotheses  on  funct ions  of  h i s tamine  
in cl inical  ep idemio logy  (fig. 1). A new classi f ica-  
t ion has  to be found wh ich  does  not  on ly  a l ter  
aet io logy ,  but  also pathogenes is  and  d isease  man i -  
fes tat ions ,  espec ia l ly  in the per ioperat ive  and  post -  
operat iv  e per iod .  
Presented at the meeting ,, New Trends in Anaphylactoid Risk 
in Anaesthesia >~. Nancy (France), 11-12 June 1992. 
Tir6s a part : D. Duda. 
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Fig. l. -- Classification of histamine release in the perioperative and postoperative p riod by means of its role in clinical 
epidemiology. 
Aet io logy 
In aetiology, as the first part of the causality 
chain, drug-induced specific allergic reactions 
involving antigen-antibodies (IgE, IgG4) in early 
phase and antigen-sensitized cells (T-cell) in late 
phase have no longer to be emphasized in anaes- 
thesiology. They are now a classical issue in text- 
books and guides [53, 56, 109] and the objective 
of persistent research in many groups around the 
world [54]. The 3 classes of substances mostly 
investigated include muscle relaxants, analgesics 
and hypnotics whereas plasma substitutes and con- 
trast media obtain less attention now than in the 
70-ies and 80-ies. 
Drug-induced nonspecific or pseudoallergic reac- 
tions resemble allergic reactions either in parts of 
the pathogenetic pathway or in disease manifesta- 
tions, but do not include antigen-antibody reac- 
tions or antigen-sensitized cell reactions in their 
aetiology (exposition) [15]. This does not exclude 
them as risk factors. Pseudoallergic reactions occur 
following administration of the same drugs which 
also induce specific reactions. This finding explains 
some of the competition which can be observed 
between groups working more on the immunologi- 
cal or toxicological aspects of the adverse drug 
reactions [17, 67]. However, there are at least 100 
drugs used in anaesthesia nd surgery which pro- 
duce pseudoallergic reactions [72, 83] and these 
are therefore also classical issues in anaesthe- 
siology and intensive care medicine. 
Histamine release induced by neuro-endocrine 
stimuli (e.g. the central effects of stress) or by 
neuro-inflammatory stimuli (e.g. the peripheral 
effects of stimulating pain fibers), is new in this 
classification. The reason for such an enlargement 
of the spectrum is, indeed, the considerable 
research in this field during the last l0 years and 
the demonstration of increased plasma histamine 
levels in the perioperative period which have to be 
considered as an in vivo parameter for such 
mechanisms in clinical conditions. The physiologi- 
cal pathways of the stress response include both 
the central and peripheral nervous systems. The 
nociceptive signal is transmitted by small myeli- 
nated (AS) and unmyelinated (C) sensory afferent 
fibers to the central nervous system [42], but also 
other stimuli including anxiety, starvation, heat 
loss, acidosis, haemorrhage are involved in release 
mechanisms of the endocrine-metabolic response 
to trauma [42]. Even opioids given for pain relief 
in anaesthesia can produce a large spectrum of the 
responses typically associated with stress to anaes- 
thesia and surgery including histamine release 
[105[. This rises the provocative question whether 
perioperative stress is a real surgical phenomenon 
or merely a drug-induced effect [105]. 
The role of histamine in stress is best described 
by its participation in the neuroendocrine r gula- 
tion of pituitary hormone secretion, but also in the 
regulation of some peripheral hormones such as 
the catecholamines [45]. According to KNIGGE and 
WARBERG [45] histaminergic neurons seem to par- 
ticipate in the mediation of the stress-induced 
release of ACTH, 13-endorphin, a-melanocyte- 
stimulating hormone and prolactin, but also of 
vasopressin, oxytocin, the catecholamines and 
renin. Histamine release in human subjects during 
stress will be shown in the following clinical trials. 
It will be demonstrated by elevated plasma his- 
tamine levels which will show pharmacokinetics 
and clinical symptoms resembling those after i.v. 
histamine injection [66], and not those of his- 
tamine release from mast cells in the tissues after 
histamine-releasing drugs or allergic reactions in 
which the amine invades the plasma compartment 
more slowly, but for a longer time period. 
The neurogenic-inflammatory mechanism of his- 
tamine release includes also the stimulation of 
pain fibers (C-fibers), as in the neuroendocrine 
mechanism, but via axon reflexes. These fibers 
directly stimulate mast cells by the peripheral 
release of peptidergic neurotransmitters without 
the detour via the central nervous system [19, 25]. 
HARGREAVES and DIONNE [33], have proposed a 
most exciting scheme for illustrating the relation- 
ship of several mediator systems (fig. 2) in. which 
histamine is released by substance P. However, 
many more peptides are involved in such release 
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Fig. 2. -- A model for evaluating endogenous mediators of 
pain and analgesia in clinical studies: the case of neuro- 
inflammatory elease of histamine. Trauma (upper part of the 
figure) activates a cascade resulting in the synthesis or release 
of prostaglandins, bradykinin, substance P and histamine (as 
well as other mediators not shown) The interrelationships of 
these inflammatory mediators form a positive feed-back loop 
allowing inflammation to persist far beyond cessation of the 
acute injury, From HARGREAVES and DIONNE [33]. 
mechanisms such as neurokinin A and B, 
neurotensin, somatostatin, dynorphin A, bradyki- 
nin, and in addition also vasointestinal polypeptide 
and calcitonin gene-related peptides [9, 87]. 
Histamine release due to trauma and surgery, 
however, includes still the direct effects on mast 
cells in the injured tissue which are destroyed by 
such a procedure. It is possible to denominate this 
type of histamine release as cytotoxic. Ischaemia is 
such a mechanism, but also the reperfusion injury 
after ischaemia including oxygen free radicals 
which have been studied intensively in the last few 
years [5, 20, 49, 50, 80, 97]. Thermal injury 
includes coagulation of tissue for stopping haemor- 
rhage which in conventional cholecystectomy [96] 
is involved in the << wound toilet >> after removing 
the gallbladder. Mechanical injury is the dissection 
or disruption of tissue such as liver or mediastinal 
connective tissue in liver resection or oesophagec- 
tomy [99] where histamine release was shown 
immediately after the event by increases of the 
plasma histamine level. 
Finally, however, a new mechanism of histamine 
release was really invented in the last few years : 
the cytokine-induced release which acts on a local 
basis creating a microenvironment [24] for the 
individual mast cell. This facilitates mediator 
release [10, 47]. KAPLAN et al. [40] defined his- 
tamine releasing factors as products of activated 
cells (cytokine-like molecules) that interact with 
basophils and/or mast cells to cause the release of 
histamine. Others defined cytokines themselves as 
histamine releasers or modulators of histamine 
release (IgE-mediated or. sometimes also nonspe- 
cific release): tumor necrosis factor -c~ [26, 27, 
88, 107], interleukin-3 [7, 28, 48, 81], interleukin-1 
[6, 88], interleukin-5 [7, 35, 43], interleukin-8 [4], 
granulocyte macrophage colony stimulating factor 
(GM-CSF) [7], connective tissue-activating peptide 
Ill [28, 46]. All these cytokines are produced 
(expressed) by macrophages, mast cells, endothe- 
lial cells and fibroblasts. These cells occur in many 
tissues, but also and in some species especially 
abundantly in the connective tissue of the 
peritoneum [11]. These cells respond to surgical 
injury [18]. 
Pathogenesis 
In pathogenesis, as the second part o f  the cau- 
sality chain in the epidemiological model of a di- 
sease, histamine does not only provide direct 
actions on a variety of cells (smooth muscle cells, 
endothelial cells, secretory cells) in the cardiovas- 
cular, respiratory and gastro-intestinal systems, but 
is also a marker for mast cell activation (fig. 1). 
Increased plasma histamine points to the release 
and formation of other mediators, such as tryp- 
tase, leukotrienes, complement factors and cytoki- 
nes. In this connection it must, however, be 
emphasized that drug-induced pseudoallergic his- 
tamine release can be selective, i.e. it may not be 
accompanied by the concomitant release of pros- 
taglandin D2 or leukotrienes [101]. 
Disease manifestation 
In disease manifestation, as the third part of the 
causality chain (fig. 1), histamine does not only 
produce cardiovascular disturbances and respira- 
tory reactions and/or complications (with some 
probability) in the postoperative period. Histamine 
and other mast cell products are - -  according to 
much recent research - -  also involved in metabolic 
reactions to trauma, in thrombosis, infections, fi- 
brosis and postoperative adhesions and hence have 
to be completely revisited concerning their possi- 
ble clinical relevance. Examples for these effects 
were already published in 1985 [68], but were 
augmented by recent reviews in anaesthesiology 
[84, 85]. The most comprehensive table on such 
functions of mast cell mediators, however, was 
published by WERSHIL and GALLI [110]. A modi- 
fied, simplified table is constructed in this concep- 
tual article on histamine release (table I). 
The new classification of perioperative histamine 
release illustrates that measured plasma histamine 
increase can no longer be easily taken as an indi- 
cator of tissue histamine release by an exhausting 
and detrimental degranulation process. Increased 
plasma histamine may originate from tissue mast 
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Table I. - -  Proposed roles of mast cells in biological responses 
relevant for anaesthesia and surgery. 
- -  hnmuno log ica l  p rocesses  (not specified here) 
- -  In f lammatory  processes  : 
augmentation or suppression of acute and chronic 
inflammation 
promotion of gastrointestinal mucosal damage 
promotion or suppression of angiogenesis 
promotion or suppression of fibrosis 
amplification of tissue damage secondary to physical agents 
regulation of wound healing 
promotion of fibrin deposition and/or degradation 
- -  Neop las t i c  p rocesses  : 
promotion or initiation of turnout development 
regulation of tumour-associated angiogenesis 
inhibition of turnout metastasis 
mediation of tumoricidal or tumoristatic effects 
- -  Phys io log ica l  p rocesses  : 
regulation of microvascular tone and permeability 
regulation of central nervous ystem and autonomic 
nervous ystem functions 
stimulation of epithelial fractions (gastric secretion, ion 
transport) 
regulation of cellular proliferation (connective tissue, 
capillaries, bones) 
Modified from WERSHIL and GALLI [1 lt)]. 
cells, basophils, endocrine cells (EC1 cells in the 
gastrointestinal tract) or peripheral and central 
nervous tissue. Increased plasma histamine may 
stand for its own or may be an indicator for a 
whole battery of mediators unwanted in a particu- 
lar clinical situation. Increased plasma histamine 
may be unwanted and detrimental and therefore 
the objective for an antihistamine prophylaxis [68] 
or it may be beneficial [12] and therefore not at 
all a matter to be worried about. The new and 
more differentiated classification of perioperative 
histamine release makes a careful decision making 
mandatory which depends on the specific clinical 
situation (e.g. the particular drug which is given). 
There is no way for an oversimplification, like in 
the case of other types of preoperative prophylaxis 
such as that for stress ulcer, surgical infection and 
thrombosis. 
Four recently conducted and completed prospec- 
tive and randomized clinical trials will demonstrate 
this with somewhat astonishing data and findings. 
FOUR PROSPECTIVE CLINICAL TRIALS 
FOR CLASSIFICATION OF HISTAMINE RELEASE 
Short communications were already published 
for all the trials in this article [14, 98, 102, 103] as 
well as full papers on the definition and measure- 
ment of serial histamine release in these clinical 
conditions [13, 71, 75, 96]. However, for a better 
understanding, details of the methods will be given 
in the following sections. 
Trial 1 
All 240 patients undergoing eneral surgery (age 
18-83 years, 116 male, 124 female, without a case 
history of allergy, ASA 1-3) were selected from 
the total population (4 230 patients) of the Clinic 
of General Surgery in Mainz by a defined selec- 
tion and randomization procedure [71] (1 patient/ 
day). The first patient was recruited in December 
1988, the last patient in September 1991. Only 
9 patients became drop-outs (3.75 %). Following 
final recruitment in the morning of the operation 
day the patients were allocated to one of four 
treatment policies (table II). The drugs (antihis- 
tamine prophylaxis and Haemaccel-35 therapy) 
were administered in a double-blind manner - -  a 
procedure which was proved to have been success- 
ful even with the plasma substitute. The technician 
measuring plasma histamine and the study leader 
analysing the data in a first evaluation after the 
end of the trial were also unaware of the treat- 
ment strategies (quadruple-blind design). The data 
were collected two weeks by the monitor and 
plausibility controls were performed continuously 
by one of the study leaders in each patient. After 
completing the trial performance, all cases were 
analysed first by one of the study leaders (W.L.) 
and the monitor in the same session. This analysis 
was controlled by the anaesthesiological coor- 
dinator of the study (D.D.) and critical cases were 
presented to the anaesthesiological study leader 
(W.D.). After this analysis a meeting of all mem- 
bers of the study team [71] with the advisory 
group was performed at February 13, 1992. At this 
meeting the random code was broken by a 
member of the advisory group (M. Rothmund) 
and the statistical analysis was then performed by 
the statistical coordinator who was not involved in 
the first part of the (descriptive) data analysis. 
Table II. - -  Test and control groups for the controlled clinical trial 
with H1-+ H~-prophylaxis and Haemaccel-35 therapy (Mainz- 
Marburg trial). 
Groups Treatment policies 
Test group 
Control group 1 
Control group 2 
Control group 3 
Hj + H2 prophylaxis and Haemaccel-35 
therapy 
NaCI p[ophylaxis and Ringer therapy 
H~ + H2 prophylaxis and Ringer therapy 
NaCI prophylaxis and Haemaccel-35 therapy 
H~-antihistamine : dimethindene maleate (Fenistil ®, Zyma-Nyon, 
Munich), tt2-antihistamine : cimctidinc (Tagamct ®, Smith Kline Beecham, 
Munich). Haemaccel-35 (polygelinc, Behring AG, Marburg). For doses and 
furthm" conditions ee LORENZ et al [71]. 
For understanding the difficult time relationships 
in this routine study in the preoperative period, 
treatments and investigations in the single patient 
are shown in figure 3. Following premedication 
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Fig. 3. Schcmatic description of 
thc treatments and investigations in 
a single paticnt of the Mainz-Mar- 
burg trial. 
D = diazepam, H = heparin, M = 
miscellaneous, depcnding on medica- 
tion for specific perioperative risk 
(hypertension, diabetes, etc.). HA- 
- randomization, PA = peripheral 
access, A = alcuronium, O = oxy- 
gen, F -  fentanyl, T = thiopental, 
S = suxamethonium, N = nitrous 
oxide, E -  enflurane, IN intuba- 
tion, GT = gastric tube, VC = va- 
soconstrictors, SM = stabilizing me- 
dications for haemodynamics, respi- 
ration and the electrolyte and acid- 
base systems. AB - antibiotics (me- 
tro-nidazole, cefuroxine), SI skin 
incision. H~ H~ dimethindene 
(0.1 mg / kg i.v.) + cimetidine 
(5 mg / kg i.v.) connected to the in- 
fusion of Ringer solution. 
with flunitrazepam p.o. and insertion of two 
peripheral-venous accesses, the basic data were 
collected for heart rate (ECG), blood pressure 
(Dinamap ®) and plasma histamine. According to 
the exact time schedule (fig. 3) measurements and 
blood sampling were carried out after the antihis- 
tamine H-  + H~-prophylaxis (dimethindene male- 
ate, 0.1 mg • kg -t, Zyma Company (Munich, 
Nyon) and cimetidine, 5 mg-kg  l, Smith Kline 
Beecham (Munich) or placebo, after alcuronium, 
fentanyl and thiopentone for induction of anaes- 
thesia, after suxamethonium and intubation, after 
maintenance of anaesthesia with N20/O2 and 
enflurane, after administration of a full relaxing 
dose of alcuronium and slow infusion (20 min) of 
a plasma substitute (Haemaccel-35 or Ringer, 
500 ml/patient) for haemodynamic stabilization. 
Finally, antibiotics were given (cefuroxime, me- 
tronidazole) in about half of the patients before 
start of operation (skin incision). All physical 
measures in the period of investigation such as 
insertion of the gastric tube, transport and posi- 
tioning were also exactly (min per min) recorded. 
This will be important in analysing the exact time 
of application for all interventions of the active 
anaesthesist in the phase of stabilization of the 
patient (infusion of plasma substitute). It should 
be emphasized that the anaesthesist performing 
the anaesthesia and that observing the whole pro- 
cedure were always different persons. The status 
of training and education in anaesthesiology was 
assessed for both the acting and the observing 
anaesthetists and was in agreement with good 
standards of treatment. 
Trial 2 
The cross-sectional study [102] was designed and 
conducted according to LORENZ et al. [76] with 
features of well-designed observational studies 
(similar to randomized trials). They included com~ 
plete protocol before start (including approval by 
ethical committee), elimination of Berkson bias 
(only hospitalized, surgical patients), defined en- 
trance criteria for cases and controls, assignment 
to groups not predictable, balanced assignment 
(10subjects in each group), prognostic factors 
(e.g. ASA classes) distributed uniformly, diagnos- 
tic information identical for both groups, assign- 
ment of patient's samples to histamine assay by 
randomization, quality control of the assay and 
drug interference monitoring. These rigid criteria 
were fulfilled by selecting 10 patients in a normal 
ward in the Department of General Surgery on 
day 5 after operation, without infection or other 
surgical complications, in the morning as in the 
case of the 10 patients in the control group who 
were prepared for operation in the parallely ongo- 
ing trial with histamine antagonists (Mainz-Mar- 
burg, trial 1). Blood samples were taken at exactly 
the same time in the resting patients on the ward 
as in the patients during induction of anaesthesia 
(fig. 3). The 2 x 10 patients in the study had an 
age between 18 and 80 years, included both sexes 
in equal proportions and showed a preoperative 
risk of ASA 1-3. This trial was repeated one year 
later in another 2 x 10 patients using the same 
design of the study. 
Trial 3 
The prospective study [103] was designed and 
conducted with the same rigid criteria as the cross- 
sectional study in trial 2, with the exception of a 
control group and these parameters which refer to 
that. The 12 patients had an age of 58 [42-84] 
years (median and range), a sex of 8 males and 
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4 females and again ASA classes 1-3. The endos- 
copy of the upper gastrointestinal tract was per- 
formed routinely, but the psychometric interview 
including a 2-step audiovisual ring scale for mea- 
surement of anxiety in a modification of the 
method of ANDREWS [2], the ECG recording and 
the blood sampling was added to the usual proce- 
dure. In addition, the patients were prepared for 
the study in a separate room before announcement 
of the start of endoscopy, then they were transfer- 
red to the endoscopy unit. The. defined time 
periods for measurement included 2 min after 
peripheral venous access, after 10min waiting, 
after the announcement of endoscopy (acute anxi- 
ety), at the deepest point of endoscopy (duodenal 
C), after completing endoscopy and after a 30 min 
recovery period. Catecholamines were not deter- 
mined after the peripheral venous access because 
for methodological reasons this value was always 
considered as << artificially ,> elevated [8]. The 
value 30 rain after endoscopy served as a base-line 
plasma catecholamine l vel. 
Trial 4 
The prospective study was again designed and 
conducted with the same rigid criteria as the cross- 
sectional study in trial 2 [98]. For instance, quality 
control was performed for each single patient and 
drug interference was carefully monitored for all 
histamine and catecholamine assays. Because of 
symptomatic holelithiasis 11 patients underwent 
laparascopic holecystectomy. Their age was 19- 
56 years, 10 were female, only one was male, and 
they showed a perioperative risk of ASA classes 
1-3. The protocol for anaesthesia was standardized 
and included vecuronium and methohexitone as 
drugs with a low potential of histamine release. 
The measurements and taking of blood samples 
for plasma histamine and catecholamine levels 
were carried out 10 and 5 min before starting 
operation (insertion of the Veress needle) (B1 and 
B2 as basal values 1 and 2), every rain after 
insertion of the first trocar and the second trocar 
for 5 rain as a specific phase in laparascopic 
cholecystectomy. As a phase of operation which is 
similar in conventional cholecystectomy as in 
laparascopic holecystectomy, the dissection of the 
gallbladder from the liver bed was chosen. This 
period was simply and intuitively divided into 
5 periods corresponding to the start of dissection, 
after 1/3, after 2/3 and after complete dissection of 
the gallbladder from the liver bed and exactly 
5 min after the removal of the organ from the 
liver bed. 
Methods applied in all four trials 
Measurements and statistics 
They were described in detail in the protocol of 
the Mainz-Marburg trial [71], but also in the origi- 
nal paper about the second trial [75] and shortly 
in the short communications [98, 102, 103]. It is 
important o emphasize that all the four trials used 
the same rigid criteria for the fluorometric- 
fluoroenzymatic plasma histamine assay as 
described by LORENZ et al. [58] and modified by 
LORENZ and NEUGEBAUER [73] and demanded in 
the Consensus Conference on Histamine Assays 
[74]. Plasma catecholamines were determined by a 
HPLC-technique [21]. Heart rate and blood 
pressure were assessed by physical methods which 
are standard today (ECG monitoi-ing, Dinamap ®). 
The statistical analysis with methods given in 
results was performed by using SAS statistical soft- 
ware. 
Definition of histamine release 
and of a systemic histamine release reaction 
The criteria which had to be fulfilled were 
described in detail by LORENZ et al. [64, 66, 68], 
DUDA et al. [13] and STTrER et al. [99]. 
However, histamine release as measured by an 
increase of plasma histamine, and histamine 
release reactions are different variables. Histamine 
release is a biochemical parameter, histamine 
release reaction is a clinical reaction which is diag- 
nosed by the clinician using a set of signs and 
measurements [75]. According to LORENZ et al. 
[66] histamine release reactions show 3 grades of 
severity: cataneous, systemic and life-threatening. 
Only systemic (grade II) and life-threatening 
(grade lII) reactions were considered in this com- 
munication. 
RESULTS OF THE FOUR CLINICAL TRIALS 
FOR CLASSIFYING HISTAMINE RELEASE 
BY AETIOLOGICAL MECHANISMS 
Trial 1 : Drug-induced pseudoallergic histamine release 
The Mainz-Marburg trial on histamine release 
and cardiovascular and respiratory disturbances in 
the preoperative period served as an excellent 
possibility for classifying different types of his- 
tamine release. Some of the conditions for that 
were planned: polygeline (Haemaccel ®) chosen 
as a nonspecific histamine releaser inducing 
pseudoallergic reactions [65], was applied delibera- 
tely in the post-induction phase of anaesthesia 
with its clinically demanded steady state and was 
administered to patients who received either 
placebo or H~- + H2-antihistamines introducing 
specificity and causality into the classification. 
However, the high incidence of histamine 
release in every phase of the preoperative period 
(table lII) was not planned at all: the inves- 
tigators were shocked, but continued the trial in 
agreement with the advisory group because what 
the trial investigated was simply clinical routine. 
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Table III. - -  Incidence of histamine release during preoperat ive 
anaesthesia and preparation of the patient for  surgery. 
Drugs and measures 
Incidence 
(n) (%) 
Antihistamines 39 16 
Alcuronium (low dose) 32 13 
Fentanyl 39 16 
Thiopentone 32 13 
Succinylcholine-in tubation-enflurane 36 15 
Alcuronium (high dose) 37 15 
Plasma substitute 71 30 
Antibiotics 31 13 
Total preoperative preparation 173 72 
n = 240 patients, drop-out cases were not treated separately. In the phase of 
antihistamine prophylaxis half of the patients received placebo (NaCI), half 
of them Hi- + He-antagonists. In the phase of plasma substitutes again half 
of the patients received Ringer as a , placebo ,, solution and half of them 
Haemaccel-35. In the phase of antibiotics about half of the patients received 
the drug, half of them did not depending on the type of operation, but not 
on randomization. All other drugs were given to all patients in study. From 
DuDA et al. [14]. 
People may point to Haemaccel ®. The findings, 
however, with the other drugs used relativate such 
a conclusion drawn at a first glance_ On the con- 
trary, Haemaccel ® proved very suitable for not 
only classifying drug-induced pseudoallergic his- 
tamine release, but also for finding the clinical 
signs of such reactions in the perioperative period 
which are different from those in a conscious 
subject taking only a single drug. In addition, the 
clinical relevance of histamine release could be 
demonstrated at least for that phase. Hence 
Haemaccel ® was a scientific stroke of luck. It 
changed current paradigms on histamine release in 
clinical anaesthesia. This will be demonstrated by 
case reports (fig. 4 and 5) which are more illustra- 
tive for the clinicians than the nude numbers in a 
contingency table. 
First of all, systemic histamine release reactions 
occurred not only in the Haemaccel group, but 
also in the Ringer group and with an incidence 
(8,5 %) which by no means was negligible. It was 
reduced by the antihistamine prophylaxis to an 
extend of 75 %. In the Haemaccel-35 group sys- 
temic and life-threatening histamine release reac- 
tions (severity grade II and I I I)  occurred in 32 % 
of the patients - -  an incredibly high incidence. 
They were reduced to an incidence o f  14 % in the 
group with antihistamine premedication which was 
statistica!ly significant (p < 0.03) (chi 2 test). 
There was one case of intraoperative death in 
the whole trial. The patient with oesophageal 
cancer (N ° 220/ASA 2) developed ventricular fi- 
brillation after considerable blood loss which was 
judged as the cause of the severe reaction - -  until 
plasma histamine data were available: histamine 
levels of 12 ng• ml ~, were associated with 
hypotension which was successfully treated, but 
not with any cutaneous igns. Histamine is highly 
arrhythmogenic [55], and the severe incident did 
not happen in any other group of the trial, but in 
the placebo-Haemaccel group where most of the 
other reactions also occurred. A confounding 
effect of histamine re lease and blood loss could 
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Fig. 4 (a, b). - -  The two patients with life-threatening histamine release reactions in the Mainz-Marburg trial. 
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not be excluded as the cause of ventricular fibrdla- 
tion and is the most likely explanation. 
The two other reactions of high severity 
(grade III = life-threatening) are self-explanatory 
(fig. 4a, b). Since these two occurred both in the 
placebo group, their incidence was not in the 
range 1 : 1000 or 1 : 10,000, but as high as 2 :  
116 or 2 %. These two cases were described in 
detail elsewhere [13], and for this reason only a 
few details are mentioned: 
- -Pat ient  N ° 24 with gastric cancer, ASA 3, 
showed 10 min after start of the Haemaccel ® 
infusion a severe decrease of blood pressure down 
to 40 mmHg, i.e. shock values. This hypotension 
occurred in combination with bradycardia (not 
tachycardia) and made emergency treatment man- 
datory. The plasma histamine levels were consis- 
tent with those of a life-threatening reaction [77]. 
- -  Patient N" 136, a 51 years old woman with 
pancreatic cancer, ASA 2, developed a similar 
severe reaction. The further increase of plasma 
histamine after administration of the antibiotics 
and emergency treatment is here of special inte- 
rest. Since, however, emergency treatment in com- 
bination with Hj + H2 blockers as treatment pre- 
ceeded this further increase it may have shown no 
further haemodynamic consequences. 
In another class of clinical judgement fell those 
systemic histamine release reactions which com- 
prised 12 patients (20 %) in which the anaesthetist 
acted with measures for stabilizing haemody- 
namics. Retrospectively most of these reactions 
were kept in mind as << uneventful ~ meaning 
<< business as usual ,, because anaesthetists expect 
some cardiovascular instability after induction of 
anaesthesia. However, they cannot think about the 
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cause of these reactions if no cutaneous or bron- 
chospastic clinical signs are recognized. What, 
however, is most remarkable in these reactions is 
the small increase in plasma histamine levels at 
which they occur -  apparently at a time when the 
patient is more susceptible, more triggered [37] to 
the effects of histamine by the load of drugs which 
he has already received. The causal role of his- 
tamine in these reactions of cardiovascular instabi- 
lity is best demonstrated by the finding that also 
5 reactions occuring after Ringer solution included 
intervention of the anaesthetist whereas all reac- 
tions in the H~ + H 2 group including Haemaccel ® 
were  not associated with a severity which was 
judged by the anaesthetist as needing an interven- 
tion. In the Haemaccel group with placebo pre- 
medication this occurred only in 3 patients as the 
lowest class of clinical judgement (~ not relevant 
for an intervention ,). 
To illustrate this new dimension of the clinical 
problem with histamine release 4 of the 12 cases 
will be presented in detail (fig. 5a-d). 
- -  Patient N ° 43, ASA 3 (fig, 5a) was hyperten- 
sive with blood pressure values up to 180 mmHg 
systolic until endotracheal intubation was com- 
pleted. Thereafter enflurane gas concentration was 
reduced before injection of the full relaxation dose 
of alcuronium. Five minutes after start of the 
infusion of Haemaccel-35, intervention with a vas- 
opressor (Akrinor ®, theophylline derivative in 
combination with theodrenaline) and fast infusion 
of additional Ringer's solution was necessary to 
maintain a blood pressure level of 106 mmHg sys- 
tolic. The histamine plasma level at this time had 
increased from 0 .26ng-ml  I to 0 .67ng-ml  -j. 
Bradycardia down to 50 b -min  J was treated by 
atropine 0.5 mg i.v., fast infusion of Ringer's was 
continued. Although the plasma histamine level 
had increased up to 1.49 ng - ml i until the end of 
the Haemaccel-35 phase, this treatment was effec- 
tive enough to increase the heart rate to at least 
77 b - min -~ and to bring the blood pressure up to 
126 mmHg sys to l i c -  but only for a short time. 
- - In  patient N°57, ASA 1 (fig. 5b), no 
dramatically severe haemodynamic reactions occur- 
red. However, in the Haemaccel ® phase the 
anaesthetist intervened four times to counterba- 
lance long lasting hypotensive ~, tendencies ~ - -  by 
reduction of anaesthetic gas concentration, by 
rapid volume infusion and even injection of a 
corticoid after the appearance of cutaneous igns. 
Finally, following cortisol injection - -  a further 
increase of plasma histamine which was accom- 
panied by bradycardia was treated with atropine. 
- -  Patient N ° 83, ASA 2 (fig. 5c), had a basi- 
cally elevated histamine level which further 
increased during intubation and plasma substitute 
infusion. Systolic blood pressure was around 
90 mmHg, 5 min after start of Haemaccel-35 infu- 
sion and enflurane concentration was reduced. 
Infusion speed of the plasma substitute was 
increased two times and two injections of a vaso- 
pressor (Akrinor ®) were regarded as necessary to 
rise the blood pressure, but without success_ 
Treatment without success can be regarded 'as a 
clinical sign of the effects of histamine release in 
that situation. 
- -Pat ient  N ° 147, ASA 2 (fig. 5d), showed 
even more such a haemodynamic reaction with 
many interventions of the practising anaesthetist. 
Reduction of gas concentration, injection of vaso-, 
pressor and therapy with volume was tried to 
counterbalance the low systolic blood pressures 
between 84 and 95 mmHg. There was almost no 
success. Plasma histamine levels rose to 
1.38 ng-  ml J only m not a dramatic increase for 
so many interventions. This was not observed in 
the group with Hj + H2 receptor antagonists. 
Some characteristics of histamine release in the 
plasma substitute phase of the preoperative period 
were combined to explain why this clinically rele- 
vant histamine release was classified as drug- 
induced pseudoallergic histamine release. 
- -F i r s t  of all, 7 of 18 systemic histamine 
re lease reactions including those with grade IIl 
(life-threatening) were associated with plasma his- 
tamine levels below 1 ng - ml i (40 %). This jus- 
tifies strongly the new definition of histamine 
release reactions. In addition, histamine release 
reactions were associated with bradycardia in the 
full setting of induction and maintenance of anaes- 
thesia. This is different from the conscious human 
subject [66]. 
- -  Cutaneous reactions occur frequently in the 
conscious volunteers, but are more rare after 
induction of anaesthesia (only in 28 % of the 
cardiovascular reactions associated with histamine 
release). This explains underreporting and many 
discussions about the clinical relevance of his- 
tamine release (wheals are not relevant, but car- 
diovascular disturbances cannot be ignored) ! 
- - In  many cases (60 %) the late time of 
response and the pharmacokinetics of histamine 
release are in favour of a pharmacological, not an 
immunological response. The large amount of pro- 
tein should produce allergic reactions with protein- 
conjugate complexes almost immediately, but 
the observed responses occur quickly with 
Haemaccel ® if applied within 3 min [66], but late 
if applied within 20 rain. These findings in the life- 
threatening cases clearly support a considerable 
importance not only of allergic, but also of 
pseudoallergic reactions [17]. 
- -A  combination of drugs as triggers for the 
Haemaccel ® and even for the Ringer response 
cannot be ruled out. Examples were given for 
nalbuphine versus fentanyl [12]. Carry-over effects 
of histamine release by alcuronium, however, did 
not play an important role. 
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- -F ina l ly ,  from all clinical judgements in this 
phase of the preoperative management of the 
patient it is obvious that drug-induced pseudoaller- 
gic histamine release is an unwanted reaction 
(adverse reaction). That this is emphasized seems 
rather surprising, but this clear judgement does 
not hold true for the other following types of 
histamine release. 
Trial 2:  Neuro-endocrine induced histamine release. 
A temptative interpretation 
The cross-sectional trial on serial histamine 
release in the preoperative preparation of the sur- 
gical patient versus changes in plasma histamine 
levels at the same time in patients of a normal 
ward-was conducted to test a hypothesis rising 
from the high incidence of histamine release in the 
Mainz-Marburg trial. It was questioned whether 
this high incidence was due to specific events in 
the preoperative period, not due to even minor 
stressors in daily life like insertion of a catheter, a
hand grip, unpleasant talks, cough or pain during 
blood collection [108[. In addition to such factors 
of influence it was asked whether failures in blood 
sample taking and plasma preparation unavoidable 
in single cases would be able to produce spikes of 
increases in plasma histamine pretending histamine 
release even if trained and experienced technicians 
carried out this procedure. 
The answers to these two questions were clearly 
<< no >> (fig. 6a, b ) :  because the questions were 
very important for interpreting the data of the 
Mainz-Marburg trial the cross-sectional study was 
later on carried out a second time and produced 
the same answers. 
However surprisingly, the plasma histamine 
levels remained not constant, but showed a steadily 
decrease over time from 0.25 (0 .12-  0 .39)ng-  
mi -l (median-range) to 0.09 (0.03 - 0.26) 
ng-ml  I after one hour. The persistent decrease 
was observed not only in the group of patients, but 
also in each individual subject. A series of findings 
let us suggest that the higher plasma histamine 
levels at the beginning than those later on were 
elicited by stress (venepuncture, anxiety, pain, 
awareness of a clinical situation with not com- 
pletely certain consequences). First of all, such 
plasma histamine levels decreased after anaesthesia 
m man and animals [61] like those of plasma 
catecholamines [91, 92] <~ in the course of the 
neuroendocrine stress response >>. They decreased 
steadily with time •again like those of plasma 
catecholamines [89, 92, 108[, and a mutual influ- 
ence of both types of biogenic amines on their 
release is also well known from the literature [70]. 
In addition, histamine release in association with 
pain in a dentist's chair was demonstrated [90]. 
Combining these findings with the data from the 
literature in the first part of this article (especially 
KNIGGE and WARBERG [45]) made such an interpre- 
Plasma Hlatamine (ng/ml) 
iii l!!t!!tli 
: ler.acc. 5 20 23 26 30 in tub  35 4(] 55  60 (mm) I
| median and range, n=lO 
Plaarna Hiram|no (ng/m|) 
5.0 
4,0 
3.0 
2.0 
p l r . |¢C_  5 20 23 
"~ median and range, n= 10 
/ 
/ 
/ 
20 30 In tub  36  40  55 60 (ram 
patient NO. 68 
Plasma Histamine (ng/ml) 
0.5 
0.4 
0.3 
0.2 
0.1 
o 
• normal ward n=lO 
c) 
, , , , • , , , , , 
~er.acc. 5 20 23 26 30 intub 35 40 55 60 (rain) 
° operat.lheatre n= 116 ,6 operat.theatre n = 115 
( p lacebo  ) ( B I+H2 prophyl=KIs  I 
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theatre. 
per. acc. = peripheral access (venepuncture) ; intub. - intuba- 
tion. For further information see LORENZ et al. [75]. 6a:  
patients in the normal ward (in supine position). 6b:  one 
patient of the 10 in the cross-sectional study undergoing real 
anaesthesia. 6c:  all patients within the Mainz-Marburg trial. 
Two groups comprise those with antihistamine or placebo pro- 
phylaxis. 
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tation of the higher plasma histamine levels at the 
beginning of procedure likely which attempted to 
imitate the preparation of the surgical patient. 
If this was true then it should be expected that 
on the average (median) such a decrease in 
plasma histamine levels should also be expected in 
the patients of the Mainz-Marburg trial. This was, 
indeed, the case (fig. 6c) - -  but only until the end 
of the induction of anaesthesia since in the plasma 
substitute phase thereafter histamine release was 
much more common_ This may have increased the 
median. 
This basic, longlasting (in contrast to the drug- 
induced release with a half life of only few rains) 
and as neuroendocrine classified histamine release 
elicits several questions which cannot yet be ans- 
wered: where does this histamine release come 
from ? From tissue mast cells, mast cells in the 
vessel walls, basophils, neuronal or brain tissue ? 
Is its mechanism not degranulation, but continuous 
intracellular histamine release [106] ? Does it 
occur after other stressful situations like intubation 
where catecholamines also rise [32, 95] ; and is the 
case shown in fig. 6b already an example for 
that ? Which factors define the pharmacokinetics 
of this histamine release if compared with his- 
tamine injection, infusion or drug-induced 
pseudoallergic histamine release from tissues [62, 
66] ? Finally, is this neuro-endocrine histamine 
release unwanted (adverse), negligible or benefi- 
cial [12, 79] ? No answer can be given yet_ 
Trial 3: Neuro-endocrine induced histamine release. 
A more definite model 
In the definition of stress by MoRsE et al. [82] 
this complex life and clinical scenario includes 
3 components:  stressors, individual make-up and 
the stress response. All three components guaran- 
tee a high variability in measured physical and 
biochemical parameters which also for stress- 
induced histamine release predicts non-responders, 
responders and superresponders a in the case of 
drug-induced pseudoallergic histamine release [63, 
66, 75]. Upper gastrointestinal endoscopy with 
modern (small diameter) equipment, but without 
premedication in patients undergoing routine 
endoscopy (age about 50, with concomitant dise- 
ases) comprises many factors of stress in all three 
subgroups [82]: 1) physical and several psycholo- 
gical stressors, especially anxiety ; 2) make-up fac- 
tors including age, personality (type As vs  type 
Bs), traits and attitudes, emotional instability, 
etc. ; and 3) factors altering the stress response 
such as the degree of perceived control, current 
mood and stress perception. 
For this reason, endoscopy as a stressful situa- 
tion was chosen as a model in which the stress- 
induced histamine release was systematically inves- 
tigated. The psychometric test with its two scales 
Raema histamine [rig/raft 
• single vakJe 
marian 
13.0 
3.0 
2.0 
• • 
1,0 
8,8 
accesa  
o.0 
• 13 ,3  
| 
i " 
oOo • • O•  
• 00  • 
i i i 
waiting announcement performance 
of start (duodenum) 
• O • 
• O•  
- - - - -  o ' - t=-  
g ig  
, I 
end recovery 
Phases of the endoscopic procedure 
Fig. 7. --  Histamine release before and during upper gastroin- 
testinal endoscopy without premedication i  patients of the 
routine programme of a surgical clinic. Single values and 
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In one superresponder endoscopy elicited plasma histamine 
levels up to 13 ng. ml J which were usually only found in 
severe anaphylaxis. For further explanations see text. 
differentiated between anxiety and depressed 
mood. Plasma catecholamines were chosen as 
quickly increasing and decreasing biochemical vari- 
ables and were compared with plasma histamine 
levels. Finally heart rate was chosen as a more 
sensitive parameter than blood pressure for 
changes in haemodynamics and was used as a 
physical variable of the stress response. 
Indeed, histamine release occurred during 
endoscopy with an increase of plasma histamine 
within the expected great variation (fig. 7). How- 
ever, none of us would even have expected that in 
one case plasma histamine levels were obtained 
which corresponded with 13.3 ng- ml i  to those in 
life-threatening allergic and pseudoallergic reac- 
tions (grade III). Histamine rose also on the aver- 
age, but much less pronounced (fig. 8a) than in 
the one exceptional case (fig. 8b). In contrast to 
the patients in the normal ward (trial II), resting 
and supine position did not lower the plasma 
histamine levels, but raised them indicating his- 
tamine release - -  in agreement with anxiety and 
in contrast o the catecholamine l vels which were 
fairly normal and corresponded ~ also to those 
30 rain after ending endoscopy (recovery) - -  a 
time which was deliberately chosen from all 
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highest plasma histamine levels. 
catecholamine studies [108]. During performance 
of endoscopy histamine and the catecholamines 
increased in plasma both on the average (fig. 8a) 
and in individual cases (fig. 8b). The heart rate 
also increased on the average, but not considera- 
bly (61, 37, 92, 63, 79, 77 b - ra in  J). In the 
exceptional case the highest increase in heart rate 
(40 b - ra in  l) of all patients was observed, but 
neither clinical signs of shock nor respiratory and 
cutaneous signs of an allergic or pseudoallergic 
reaction. 
The considerable increase in plasma histamine 
(basa l  0 .18 ng .  m1-1,  dur ing  endoscopy  
13 .3ng-ml  '=  7400 %) is not reflected in a 
similar increase in plasma catecholamines. Their 
increase corresponds to , modest stress >>, compa- 
rable to that observed on the average after vene- 
puncture [108] or in the anaesthesized patient dur- 
ing coronary by-pass surgery [36, 100]. In addi- 
tion, the rise in histamine on the average occurs 
earlier than that in the catecholamines if the va- 
lues in the recovery period are taken as controls 
(fig. 8a, b). Hence it is concluded that stress- 
induced (neuro-endocrine induced) histamine 
release exists in human subjects in clinical condi- 
tions and that it has to be distinguished from 
drug-induced pseudoallergic reactions in anaes- 
thesia and surgery. 
Mainly two questions arise from these findings 
which can temptatively be answered : 
1) Where is so much histamine released to 
increase the plasma histamine levels up to con- 
centrations found in anaphylactic shock ? If it is 
neuroendocrine in origin, does it originate from 
the brain ? Histamine is released into cerebrospi- 
nal fluid [43, 44} where it shows an approximately 
30-fold higher concentration than in plasma. In 
addition, it is rapidly metabolized [30], but anaes- 
thesia and especially muscle relaxants may inter- 
fere with that [22, 34, 57]. Histamine as a neuro- 
transmitter has found its role in neuroendocrine 
reactions (stress reactions) [29, 38, 39, 45] espe- 
cially in endogenous non-opiate analgesia and is 
therefore centrally related to pain [38, 100], condi- 
tions which occur during endoscopy as well as 
fundamentally in surgery. Histamine release in the 
central nervous system is supposed to come from 
mast cells, from vascular smooth muscle, from 
unidentified cells which are neither neurons nor 
mast cells, from pineal body being influenced by 
sympathetic activity, or from nervous tissue in the 
midbrain [29]. 
2) If histamine rises in plasma up to such levels 
in the neuroendocrine response why does it not 
produce an anaphylactoid shock as in severe aller- 
gic and pseudoallergic reactions ? An easy answer 
to that may be the functional antagonism of the 
catecholamines, but it is not as likely as another 
explanation : even a small dose of exogenous his- 
tamine (0.45 ng-  kg l) injected intravenously as a 
bolus - -  to imitate the sudden increase of plasma 
histamine after intravascular release from basophils 
[66], produced plasma histamine levels in a human 
volunteer which rose as high as 20ng-ml  -I 
whereas the median increase of the group of 
volunteers was only 0.9 ng.  m1-1 after the same 
dose. Fortunately, these volunteers received the 
dose of histamine 4-times during a day, and hence 
this phenomenon could be reproduced in this par- 
ticular volunteer. He showed a strong tachycardia 
to histamine, but only a minor decrease of blood 
pressure (10 mmHg !) and resembled clinically the 
one patient during endoscopy. 
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From such findings we speculate that neuro- 
endocrine induced histamine release originates 
from other sources than pseudoallergic histamine 
release. The first originates from cells or tissues 
which are relatively low in histamine content, but 
from which histamine enters the plasma directly 
like a histamine bolus injection (e.g. from 
basophils). The second originates from histamine- 
rich tissues from which it is released from connec- 
tive tissue mast cells and enters the plasma com- 
partment more slowly and in a smaller proportion 
of the totally released histamine than in the case 
of a histamine bolus injection. Hence the clinical 
Signs of histamine release in this aetiological type 
of release are more due to the large amount of 
free histamine in the tissue and in the neighbour- 
hood of effector cells (smooth muscle cells, etc.) 
than due to the rise in plasma histamine. 
The neuro-endocrine induced histamine release 
seems to produce clinical effects such as tachycar- 
dia which are, however, at present indistingui- 
shable from the effects of catecholamine release. 
Because of that confounding effects no decision 
can be made whether it is unwanted or beneficial, 
but it seems unlikely that it is negligible. 
Trial 4:  Laparoscopic cholecystectomy :
a complex scenario of intraoperative histamine release 
It is most l ikely that choleeystectomy for reasons 
which were explained in the first (classification) 
chapter of this article combines several types of 
histamine release: 1) The neuro-endocrine and 
neuro-inflammatory induced types in the trocar 
phase with pain via the substance P pathway and 
pain via the central nervous system ; 2) the 
cytotoxic and cytokine-induced types in the phase 
of gallbladder dissection from the liver bed. The 
data which were obtained supported this hy- 
pothesis. 
The placement of the first and second trocar 
through the abdominal wall (fig. 9) was charac- 
teristic of a shortlasting- punctually painful 
stimulus which was promptly answered by a short- 
lasting increase and decrease of plasma histamine 
(the histamine injection type as we have called it 
in trial 3). The increase was up to 3 r ig -ml  -], 
more than 10-times the level of the base-line and 
occurred with a certain incidence, as expected 
from the complexity of stress. However, 5 of 
11 patients reacted - -  a considerable proportion of 
patients. The increase of histamine was accom- 
panied by an increase of both epinephrine and 
norepinephrine - -  but not in all and not always in 
the same patients. Histamine release in patients 
without catecholamine release may indicate the 
neuro-inflammatory type of release from mast cells 
m the peritoneal connective tissue. 
During the removal of the gallbladder from the 
liver bed the increase and elimination of histamine 
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Fig. 9. - -  Histamine release in the phase of trocar placement 
in laparoscopic holecystectomy. 
Single values obtained from individual patients. Each patient 
has his specific graphical sign. Reacting subjects and nonres- 
ponders are separated by the criterion of increases in plasma 
histamine by more than 3 SD of the variation of the histamine 
assay. 
was lower than in the trocar phase (fig. 10). The 
longlasting elevation of plasma histamine points to 
a continuing trauma with cytotoxic release due to 
stopping haemorrhage by coagulation, especially in 
the second half of gallbladder dissection. The role 
of cytokines in augmenting the response cannot be 
ruled out for the second peak since they are 
certainly produced by peritoneal macrophages in 
the course of preparation in the Calot's triangle 
and in the beginning of the dissection. Interesting 
and in agreement with the proposed mechanisms 
of histamine release - -  there was no increase in 
catecholamines in this phase of operation. 
At present, no cardiovascular eactions were 
observed in the second phase of operation - -  
despite plasma histamine levels of 4 ng-ml  l 
which after i.v. histamine injection are always 
associated with at least tachycardia. The reasons 
for this inconsistent finding are not clear, but it is 
at present impossible to associate any judgement 
(unwanted, beneficial) with intraoperative, 
cytotoxic histamine release. Only in the reperfu- 
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Fig. 10. - -  Histamine release during retrograde removal of gallbladder from liver bed in 
laparoscopic cholecystectomy. Single values obtained from individual patients. Each patient 
has his specific graphical sign which corresponds to that in fig, 9 for easy comparison. 
Reacting subjects and nonresponders are separated by the criteria of increases in plasma 
histamine by more than 3 SD of the variation of the histaminc assay. 
sion phase of liver transplantation i  pigs such 
unwanted effects (hypotension) could be demons- 
trated [59, 60]. 
DISCUSSION ABOUT PERIOPERATIVE HISTAMINE 
RELEASE:  ITS RESTRICTION TO CLASSIFICATION 
Although this article contains a considerable 
amount of original data, it is not conceived as an 
experimental, but as an conceptual paper. The 
classification by means of aetiology in special and 
clinical epidemiology in general was created to 
introduce a certain kind of order in a chaos of 
perioperative findings which were not available 
before the conduct of the Mainz-Marburg trial 
with its precise recording of clinical and biochemi- 
cal phenomena and its small'prospective trials 
which intended to explain the surprising data of 
this randomized study. In this connection, the data 
in the plasma substitute phase are really surpris- 
ing: they should change current opinions about 
frequency and clinical relevance of drug-induced 
pseudoallergic reactions. 
People may ask why in the last ten years this 
group has spent so much energy on classifying 
histamine release in the perioperative period. 
Indeed, there are now three types of classifica- 
tion : 
- -1 )  along the axis of severity [63, 66]: 
cutaneous, systemic and life-threatening histamine 
release reactions were distinguished by using 
methods of clinical judgement and objective medi- 
cal decision making. This classification has gained 
a wide recognition and is included in reviews [16, 
41, 51, 86] and textbooks [23] of anaesthesiology 
and allergology. It combined clinical signs with 
plasma histamine levels and was successful in the 
Mainz-Marburg trial in the phase of plasma substi- 
tute and steady state after induction of anaesthesia 
and before skin incision. 
- -2 )  along the axis of differential diagnoses 
[71, 75] : it depends on measurement of mediators 
and assessing clinical signs and has the classes : no 
reactions, histamine release without reaction, his- 
tamine release reactions, cardiovascular reactions, 
and other reactions including pseudoallergic reac- 
tions without histamine release (but that of leuko- 
trienes, etc.). 
- -3 )  along the axis of aetiology of histamine 
release (this article): drug-induced allergic, drug- 
induced pseudoallergic, neuro-endocrine, neuro- 
inflammatory, cytotoxic and local, cytokine- 
induced histamine release. 
All three classifications have only one aim: to 
evaluate the clinical relevance of perioperative his- 
tamine release and to test and demonstrate where 
an intervention with histamine antagonists and 
possibly also agonists (impromidine, arpromidine) 
[3] is necessary. As with other kinds of preopera- 
tive prophylaxis, such as antithrombotic, antiinfec- 
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tious, and stress-ulcer preventing, it is also not 
easy to define which patients should and who 
should not receive such drugs or measures for 
prevention of histamine release reactions [78]. 
Finding groups and subgroups is a general aim in 
our time which wants to tailor exactly treatments 
to individual patients. 
However, an expected clinical relevance of 
mediator release (not only of histamine) in the 
perioperative period is also derived from our 
pathophysiological understanding. 
1) For histamine, ROHER and LORENZ [94] for- 
mu la ted  << Even if it is difficult to show in a 
single case, histamine release may be important 
via a delayed effect for postoperative thromboem- 
bolic complications, for after-effects of cardiac 
arrhythmias, for manifestation of a myocardial 
infarction or for the development of ARDS and 
stress ulcer. The primarily healthy patient may 
have sufficient reserves for compensat ion of 
mediator release, but the patient at risk is much 
more endangered >>. 
2) For the modification of the Stress response, 
KEHLET [42] formulated" << Concern about detri- 
mental effects of surgery such as myocardial 
infarction, pulmonary complications, thromboem- 
bolism, impaired immunofunct ion and convales- 
cence with fatigue, inability to work etc., all of 
which may not be considered as a result of imper- 
fections in surgical technique, has therefore led to 
studies of possible blocking of the t rauma 
response. This is based upon the hypothesis that, 
by inhibit ing the surgically induced metabol ic 
response, the increased emands on various organs 
Change from 
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" \ \  
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F? I I. - -  The relatively slow effect of epinephrine (0.2 mg • 
~ body weight) on the blood glucose and tissue glycogen 
revels of the normal rat, as compared with quick response of 
the cardiovascular system to this hormone. From STRAND [104]. 
may be consequently diminished and that this may 
be beneficial by lowering morbidity in high-risk 
surgical patients ,,_ 
3) In agreement With 'such pathophysiological 
considerations i the general f inding on the diffe- 
rent duration of the effects of catecholamine 
release, if the cardiovascular system, or metabolic 
changes associated with them are considered 
(fig. 11) [104]. 
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PERIOPERATIVE NONSPECIFIC HISTAMINE RELEASE 165 
ABSTRACT : As a consequence of the performance of a randomized controlled clinical trial on periopcra- 
tire histamine release and cardiovascular and respiratory disturbances, everal types of increases in plasnra 
histamine had to be distinguished instead of only two which existed at the beginning of the study : drug- 
induced allergic and pseudoallergic reactions. First of all, the new classification by aetiology (clinical 
epidemiology) was derived from a metaanalysis (secondary analysis) of the most recent literature. 
According to that histamine release in the perioperative period has several, different causes and is 
involved in several, different disease manifestations. A clear distinction (classification), however, is 
necessary if histamine release as an unwanted (adverse) effect has to be recognized, value judged 
according to its clinical relevance and therefore also prevented by histamine antagonists. Histamine 
release by neuro-endocrine and neuro-inl' lammatory mechanisms, eytotoxic histamine release and local, 
eytokine induced histamine release have been distinguished from pseudoallergic histamine release, but its 
functions are not yet clear. It has been analysed in prospective trials which used special clinical situations 
as models : patients on a normal ward or before and during upper GI endoscopy without premedication, 
but also in specific phases of laparoscopic holecystectomy (troear phase and dissection phase). Their 
existence in the clinical reality is now very likely, but new trials must investigate the pathophysiological 
effects such as in metabolism, coagulation, pulmonary haemodynamics ( hunt volume) and gastric acid 
secretion. Histamine release by pseudoallergic mechanisms, however, was identified in the very vulnerable 
post-induction phase of anaesthesia up to skin incision. Its incidence was much higher than ever expected 
and its clinical relevance was demonstrated by the severity of reactions and the intervention strategies of 
the anaesthetists who were blinded concerning the type of the plasma substitute given and the prophylaxis 
with antihistamines. Pseudoallergic histamine release was clearly unwanted (adverse). Its oecurence in the 
other phases of anaesthesia has to be further evaluated in the tedious procedure of data analysis of the 
Mainz-Marburg-trial. The overall incidence of histamine release in the trial was so incredibly high (72 % 
of all .patients, some of them with up to 4 episodes of histamine release) that a distinction between 
pseudoallergic (unwanted) and other types of histamine release (possibly less unwanted or even beneficial) 
is urgently needed. In the phase of steady state (maintenance) of anaesthesia the HI- + H~-prophylaxis 
was highly effective. Further analysis must show whether this is also the case during the phases of 
induction of anaesthesia. Many of the pseudoallergic histamine release reactions (72 %) occur without 
cutaneous igns - -  even with plasma histamine levels of 12 ng• ml -~, i.e. in the range of usually life- 
threatening reactions. The clinical picture of these reactions has to be revised. Since in the case of 
haemodynamie nstability alone the anaesthetist cannot distinguish between histamine-induced reactions 
and cardiovascular reactions based on other mechanisms, a considerable underreporting of the reactions is 
fully understandable. Plasma histamine assays are necessary under strict quality control to create 
awareness of this considerable clinical problem. If that is understood the questions of antihistamines : yes 
or no ? to whom ? at which time ? and which drugs and dose ? will be asked in a different way than 
hitherto. 
